Literature DB >> 12519399

Changes in immune parameters and their correction in human cases of tick-borne encephalitis.

A V Atrasheuskaya1, T M Fredeking, G M Ignatyev.   

Abstract

Tick-Borne Encephalitis virus (TBEV) causes dangerous central nervous system diseases in humans. General infection leads to the development of meningitis or encephalitis, which is characterized by swelling of the brain due to inflammation. Tetracyclines may act locally to moderate inflammation in the CNS. In this study, we investigated the potential clinical benefits of administering tetracycline hydrochloride to patients hospitalized due to suspected TBEV infection presenting with fever and evidence of a recent tick bite. We also characterized an acute immune response to TBEV by profiling certain cytokines and soluble receptors in Tetracycline-treated and untreated patients. Increased serum levels of TNF-alpha, IL-1 alpha and IL-6 were found in all patients at admission. Soluble receptors presented in the serum of patients in a magnitude higher levels than the corresponding cytokines and were increasing during first weak of hospitalization. Levels of IL-10 were also rising during that period. In our study tetracycline hydrochloride acted as an immunomodulator, which was able to reduce manifestations of inflammation response during TBE course; this action led to quicker improvement of symptoms and, consequently, to a faster clinical recovery. The positive result of tetracycline hydrochloride treatment was accompanied by certain particularities in the dynamics of studied cytokines and receptors: the concentrations of IL-6, IL-1 beta, TNF-alpha dropped quicker and reached lower levels, and the concentrations of sIL-6R, IL-1RA, sTNFR1 increased faster and reached higher maximum levels in the tetracycline-treated groups. Children had the highest levels of IL-6, which were not neurotoxic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519399      PMCID: PMC1808605          DOI: 10.1046/j.1365-2249.2003.02050.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  Anti-inflammatory cytokines.

Authors:  S M Opal; V A DePalo
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

Review 2.  Tick-borne encephalitis.

Authors:  U Dumpis; D Crook; J Oksi
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

3.  [Experimental tick-borne encephalitis in golden hamsters treated with specific immunotherapy].

Authors:  G N Leonova; L M Isachkova; V G Borisevich; A Iu Fisenko
Journal:  Vopr Virusol       Date:  2000 Jul-Aug

4.  The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients.

Authors:  R Kaiser
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

5.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

6.  [Tumor necrosis factor alpha and interleukin 1-beta in serum of patients with tick-borne encephalitis].

Authors:  M Kondrusik; S Pancewicz; J Zajkowska; T Hermanowska-Szpakowicz
Journal:  Pol Merkur Lekarski       Date:  2001-07

7.  Experimental study on the possibility of treatment of some hemorrhagic fevers.

Authors:  G Ignatyev; A Steinkasserer; M Streltsova; A Atrasheuskaya; A Agafonov; W Lubitz
Journal:  J Biotechnol       Date:  2000-09-29       Impact factor: 3.307

8.  Tick-borne encephalitis virus strains of Western Siberia.

Authors:  V N Bakhvalova; V A Rar; S E Tkachev; V A Matveev; L E Matveev; A S Karavanov; A K Dobrotvorsky; O V Morozova
Journal:  Virus Res       Date:  2000-09       Impact factor: 3.303

9.  The TH1 and TH2 cytokine network in healthy subjects: suggestions for experimental studies to create prognostic and diagnostic indices for biotherapeutic treatments.

Authors:  P Pellegrini; I Contasta; A M Berghella; T Del Beato; C U Casciani; D Adorno
Journal:  Cancer Biother Radiopharm       Date:  2000-06       Impact factor: 3.099

10.  Increased plasma levels of interleukin-6 in sepsis.

Authors:  C E Hack; E R De Groot; R J Felt-Bersma; J H Nuijens; R J Strack Van Schijndel; A J Eerenberg-Belmer; L G Thijs; L A Aarden
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

View more
  21 in total

1.  Comparative analysis of immune responses to Russian spring-summer encephalitis and Omsk hemorrhagic fever viruses in mouse models.

Authors:  Bersabeh Tigabu; Terry Juelich; Michael R Holbrook
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

2.  Depletion of plasma gelsolin in patients with tick-borne encephalitis and Lyme neuroborreliosis.

Authors:  Alina Kułakowska; Joanna M Zajkowska; Nicholas J Ciccarelli; Barbara Mroczko; Wiesław Drozdowski; Robert Bucki
Journal:  Neurodegener Dis       Date:  2011-03-10       Impact factor: 2.977

3.  Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population.

Authors:  Elena V Ignatieva; Andrey A Yurchenko; Mikhail I Voevoda; Nikolay S Yudin
Journal:  BMC Med Genomics       Date:  2019-05-24       Impact factor: 3.063

4.  Escape of Tick-Borne Flavivirus from 2'-C-Methylated Nucleoside Antivirals Is Mediated by a Single Conservative Mutation in NS5 That Has a Dramatic Effect on Viral Fitness.

Authors:  Ludek Eyer; Hirofumi Kondo; Darina Zouharova; Minato Hirano; James J Valdés; Memi Muto; Tomas Kastl; Shintaro Kobayashi; Jan Haviernik; Manabu Igarashi; Hiroaki Kariwa; Marketa Vaculovicova; Jiri Cerny; Rene Kizek; Andrea Kröger; Stefan Lienenklaus; Milan Dejmek; Radim Nencka; Martin Palus; Jiri Salat; Erik De Clercq; Kentaro Yoshii; Daniel Ruzek
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

5.  Serum levels of interleukin 6 in recently hospitalized tick-borne encephalitis patients correlate with age, but not with disease outcome.

Authors:  M G Toporkova; S E Aleshin; S V Ozherelkov; M V Nadezhdina; J R Stephenson; A V Timofeev
Journal:  Clin Exp Immunol       Date:  2008-06       Impact factor: 4.330

6.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.

Authors:  Troy D Querec; Rama S Akondy; Eva K Lee; Weiping Cao; Helder I Nakaya; Dirk Teuwen; Ali Pirani; Kim Gernert; Jiusheng Deng; Bruz Marzolf; Kathleen Kennedy; Haiyan Wu; Soumaya Bennouna; Herold Oluoch; Joseph Miller; Ricardo Z Vencio; Mark Mulligan; Alan Aderem; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-11-23       Impact factor: 25.606

7.  Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever.

Authors:  J E Z Castro; I Vado-Solis; C Perez-Osorio; T M Fredeking
Journal:  Clin Dev Immunol       Date:  2011-03-28

8.  Breakdown of the blood-brain barrier during tick-borne encephalitis in mice is not dependent on CD8+ T-cells.

Authors:  Daniel Růžek; Jiří Salát; Sunit K Singh; Jan Kopecký
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

9.  May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis?

Authors:  Daniel Růžek; Gerhard Dobler; Hans Helmut Niller
Journal:  BMC Infect Dis       Date:  2013-07-03       Impact factor: 3.090

10.  Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection.

Authors:  Jincheng Chen; Mary Mah-Lee Ng; Justin Jang Hann Chu
Journal:  PLoS Pathog       Date:  2015-07-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.